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Abstract
Purpose The prospective pilot study was designed to evaluate
the preventive effects of amino-acid-rich elemental diet (ED),
Elental®, on chemotherapy-induced oral mucositis in patients
with colorectal cancer. The factors influencing its efficacy are
also investigated.
Methods A total of 22 eligible patients with colorectal cancer
experiencing grade 1–3 oral mucositis during treatment with
fluorouracil-based chemotherapy entered the current study.
Their average age was 67 years. There were 10 male and 12
female. The PS was 0 in the majority of patients. Patients
received two courses of the same chemotherapy regimen and
Elental® concurrently after recovery to grade 0 or 1 oral
mucositis.
Results FOLFOX6 + bevacizumab in 8 patients, FOLFIRI +
bevacizumab in 8 patients, FOLFIRI + panitumumab in 1
patient, FOLFIRI in 1 patient, XELOX + bevacizumab in 2
patients, and S-1 + cetuximab in 2 patients were used as first-
line (16 cases) or as second-line (6 cases) chemotherapy. Dose
reduction of 5-fluorouracil (5-FU) or oral fluoropyrimidine
was performed in the 2 patients achieving grade 3 oral muco-
sitis and in the 3 patients achieving grade 2 oral mucositis. The
maximum grade of oral mucositis decreased in 18 of the 22
patients during the first treatment course with Elental®
(p = 0.0002) and in 20 of the 22 patients in the second course
(p < 0.0001). Multivariate analyses found that the dose
reduction in 5-FU or oral fluoropyrimidine, ED intake, and
the prior administration of ED were each a significant factor
for the preventive efficacy on oral mucositis.
Conclusion The amino-acid-rich elemental diet Elental® may
be useful as a countermeasure for 5-FU-based chemotherapy-
induced oral mucositis in patients with colorectal cancer.
Keywords Chemotherapy . Oral mucositis . Elemental diet
(ED) . Nourishment academic intervention . Colorectal
cancer . Amino acid
Introduction
Mucositis is a common adverse effect of chemotherapy and/or
radiotherapy. The oral mucositis that is the mouth mucous
membrane injury causes anguish to the patient regardless of
the severity of symptoms and induces a decrease in quality of
life (QOL) and in desire for continuation of the treatment.
After oral mucositis once occurs, adjustments must be made
to the dose of the anticancer drug and to the administration
schedule, as well as requiring new preventive care to the
mouth [1]. Therefore, to continue chemotherapy as far as pos-
sible without decreasing the dose, some effective oral muco-
sitis preventive measures are needed.
The mechanism of chemotherapy-induced mucositis has
been described as occurring stepwise through a sequence of
events [2]. First, chemotherapy causes direct DNA damage
resulting in the death of basal epithelial cells and the genera-
tion of reactive oxygen species (ROS) that damage connective
tissue, DNA, and cell membranes. Second, this cell damage
causes the activation of several transcription factors including
nuclear factor-kappa B (NF-κB), wnt, and p53, and their mo-
lecular pathways. Third, these pathways are further amplified
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via positive feedback loops. Finally, cell death causes mucosal
thinning, resulting in the development of clinical and symp-
tomatic ulcerated mucositis. The generation of the oral muco-
sitis appears at around 5 to 10 days after the initiation of
chemotherapy in relation to the cell cycle of the mouth mu-
cous membrane epithelial cells. After the appearance of the
mucousmembrane injury, 2 to 3 weeks are required to achieve
recovery, since the usual regeneration cycle of the oral mucosa
is around 7 to 14 days. The period until recovery, the frequen-
cy, and the severity of oral mucositis each depends on the kind
and the dose of the anticancer drug, the treatment regimen,
and the general condition of the patient.
The incidence of oral mucositis, induced by colorectal can-
cer chemotherapy such as FOLFOX and FOLFIRI including
bolus and continued infusion of 5-fluorouracil (5-FU), and
XELOX that uses oral 5-FU, is high at 25–40 % [3–5]. Glu-
tamine is a natural amino acid which functions as a substrate
for nucleotide synthesis in most dividing cells [6]. There have
been several randomized studies to date on the use of gluta-
mine in chemotherapy- and radiotherapy-induced mucositis
with varying results [7, 8]. Another study, focused on the
action of mucous protection of the glutamine [9] in addition
to the countermeasures for oral intake trouble, suggests a pro-
spective pilot study to evaluate preventive effects of the ele-
mental diet (ED) Elental®, (one packing 80 g/300 kcal) which
contains 1932 mg of L-glutamine, on oral mucositis caused by
chemotherapy. Elental® is composed of various amino acids,
very little fat, vitamins, trace elements, and a major energy
source, dextrin. The composition of Elental® is detailed else-
where [10]. In the present study, the preventive effects of the
ED on oral mucositis and the factors influencing its efficacy
are followed prospectively, and the significance of such nour-
ishment intervention as a countermeasure is discussed.
Patients and methods
Eligibility criteria
A total of 23 metastatic colorectal cancer patients were regis-
tered prospectively after developing grade 1–3 oral mucositis
between September 2008 and December 2010 during 5-FU-
based chemotherapy involving mFOLFOX6, FOLFIRI,
XELOX, or S-1 with or without biologics. Each of these eli-
gible patients had histologically confirmed advanced or met-
astatic cancer. No patient had received prior radiotherapy or
concurrent radiotherapy. The criteria for entry into our study
included age older than 20 years, Eastern Cooperative Onco-
logic Group (ECOG) performance status ≤2, neutrophils
≥1500/mm3, platelets ≥750,000/mm3, creatinine ≤1.5 times
the upper normal limit or creatinine clearance of more than
60mL/min, and liver function tests (serum bilirubin level ≤1.5
times the upper normal limit and AST/ALT <3 times the upper
normal limit). All patients were required to be free of any signs
of systemic infection and must not have taken antibiotics.
Each patient gave written informed consent before entering
the study. The study was performed in accordance with the
Declaration of Helsinki.
Administration of Elental® and anticancer drugs
Two courses of the same chemotherapy that induced the
oral mucositis were performed with or without dose reduc-
tion in 5-FU or oral fluoropyrimidine. The chemotherapy
was then restarted according to the standard criteria of
clinical trials such as neutrophil depletions of grade 1 or
less and decrease in platelet of grade 1 or less as the
hematological toxicity, and oral mucositis of grade 1 or
less, peripheral neurological symptoms of grade 1 or less,
protein urea and hemorrhage of grade 1 or less, and diar-
rhea of grade 1 or less as the non-hematological toxicity.
In those patients experiencing grade 3 oral mucositis and
in those patients experiencing grade 2 oral mucositis
which persisted even after 7 days of next chemotherapy
delay, the chemotherapy was restarted with a dose reduc-
tion in 5-FU/oral fluoropyrimidine after all oral mucositis
recovered to grade 1 or less. The ED Elental® (80 g/
300 kcal or more per day) was given perorally in addition
to normal oral ingestion, together with chemotherapy in
each course lasting 2 to 3 weeks (on days 1–14 or days
1–21). To help the patient, the ED was flavored and made
into a jelly. Patients recorded the daily Elental® intake and
the chief physician collected the data before the next
course of chemotherapy.
Oral mucositis assessment
Chemotherapy-induced oral mucositis was graded basically
according to version 3.0 of the Common Terminology Criteria
for Adverse Events (CTCAE v3.0). The CTCAE v3.0 grades
were defined as follows: grade 0, no mucositis; grade 1, min-
imal symptoms such as pain/throat pain and erythema of the
mucosa; grade 2, obviously symptomatic but can eat, patchy
ulceration, or pseudomembranes; grade 3, obviously symp-
tomatic and cannot eat , confluent ulcerat ion, or
pseudomembranes, and bleeding with minor trauma; and
grade 4, severely symptomatic in association with life-
threatening consequences, tissue necrosis, and/or with signif-
icant spontaneous bleeding. Patients daily recordedmouth and
throat soreness and activity score that was modified from the
Oral Mucositis Daily Questionnaire (OMDQ) (questions 2
and 3) [11]. Finally, oral mucositis was assessed by inde-
pendent physician based on the patient’s self-assessment of
the mouth and throat soreness and activity score, the pre-
treatment patient interview by pharmacologists and chief
physician’s decision every week on out-patient basis for
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the study period. The maximum grade of oral mucositis at
individual chemotherapy course were recorded by the in-
dependent physician.
Endpoints and statistical methods
The ED intake in each course, the presence and grade of the
oral mucositis, and the presence and grade of any adverse
effect were monitored. Multivariate analysis for the factors
(age, gender, PS 0 vs. 1–2, usage of antiepidermal growth
factor receptor (EGFR) antibodies, pretreatment albumin val-
ue, pretreatment lymphocyte, number of anticancer drugs 2 vs.
3, regimen duration 2 vs. 3 weeks, treatment phase: first line
vs. second line, improvement in neutrophil depletion, ED in-
take, prior treatment with ED, dose reduction in 5-FU or oral
fluoropyrimidine) related to the efficacy of the ED on oral
mucositis was performed using logistic regression analysis,
and any differences were investigated using the χ2 test and
Student’s t test. Differences between groups were evaluated
by the χ2 test or G-test for categorical variables, and the
Mann–Whitney U test was used for continuous variables.
All analyses were performed using SPSS software (Version
18.0; SPSS, Inc., Chicago, IL), and the significance level was
set at p < 0.05.
Results
Patient characteristics
Among the 23 patients, one patient who had developed grade
3 oral mucositis in a prior course could not receive the che-
motherapy and the ED. Table 1 summarizes the characteristics
of the other 22 patients who completed this study protocol.
There were 10 male and 12 female, and their average age was
67 years, ranging from 44 to 84 years. The oral mucositis that
had developed in the prior course was grade 3 in 2 patients,
grade 2 in another 15 patients, and grade 1 in the other 5
patients.
mFOLFOX6 + bevacizumab in 8 patient, FOLFIRI +
bevacizumab in 8 patients, FOLFIRI + panitumumab in 1
patient, FOLFIRI in 1 patient, XELOX + bevacizumab in 2
patients, and S-1 + cetuximab in 2 patients were used as the
first-line (16 cases) or second-line (6 cases) chemotherapy.
Dose reduction in 5-FU was performed in 2 patients
experiencing grade 3 oral mucositis in the prior chemotherapy
using the mFOLFOX6 + bevacizumab regimen, and in 1 pa-
tient experiencing grade 2 oral mucositis in the prior chemo-
therapy using the FOLFIRI + bevacizumab regimen. Also,
dose reduction in S-1 was performed in 1 patient experiencing
grade 2 oral mucositis in the prior chemotherapy using the
Table 1 Patient outline




Treatment phase Gender Age PS Dose reduction
1 3 FOLFIRI + Bmab 2 First line Male 68 0 5-FU
2 3 FOLFIRI + Bmab 2 First line Female 75 2 5-FU
3 2 FOLFOX + Bmab 2 First line Male 59 0
4 2 FOLFOX + Bmab 2 First line Male 73 1
5 2 FOLFOX + Bmab 2 First line Female 82 1 5-FU
6 2 FOLFOX + Bmab 2 First line Female 84 1
7 2 FOLFOX + Bmab 2 Second line Female 67 0
8 2 TS-1 + Cmab 3 Second line Female 59 1
9 2 TS-1 + Cmab 3 First line Male 76 0 S-1
10 2 FOLFOX + Bmab 2 First line Male 63 0
11 2 FOLFIRI + Bmab 2 First line Female 73 1
12 2 FOLFIRI + Bmab 2 First line Female 73 1
13 2 FOLFIRI + Bmab 2 Second line Female 63 0
14 2 XELOX + Bmab 3 First line Male 74 1 Capecitabine
15 2 XELOX + Bmab 3 First line Female 75 1
16 2 FOLFIRI + Bmab 2 First line Male 66 0
17 2 FOLFIRI + Bmab 2 Second line Female 76 0
18 1 FOLFOX + Bmab 2 First line Female 62 0
19 1 FOLFIRI + Bmab 2 First line Male 61 0
20 1 FOLFOX + Bmab 2 First line Male 44 0
21 1 FOLFIRI 2 First line Male 66 0
22 1 FOLFIRI + Bmab 2 Second line Female 59 0
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S-1 + cetuximab regimen, and in capecitabine in 1 patient
experiencing grade 2 oral mucositis in the prior chemotherapy
using the XELOX + bevacizumab regimen (Table 1).
The average ED intake in the first course was 600 g, rang-
ing from 240 to 1120 g, and was 557 g in the second course,
ranging from 240 to 1120 g (Table 2).
Preventive effect on oral mucositis and neutrophil
depletion
Table 2 shows the grades of oral mucositis and neutrope-
nia before and after the ED treatment. The maximum
grade of oral mucositis decreased in 18 of 22 patients
during the first course and in 20 of 22 patients in the
second course, compared to those in the prior chemother-
apy course. The grade of oral mucositis was significantly
reduced by the ED treatment (p = 0.0002, prior treatment
vs. first treatment; p < 0.0001, prior treatment vs. second
treatment) (Fig. 1). The efficacy of the ED was catego-
rized as Bexcellent^ in those cases where the maximum
grade of oral mucositis was reduced by two grades or
more, as Bgood^ where the maximum grade was reduced
by one grade, and as Bno change/poor^ where there was
no reduction in the maximum grade. In those 18 patients
who received chemotherapy of a 2-week cycle, we inves-
tigated the correlation, if any, between the efficacy of the
ED (categories) and the ED intake. There was a significant
difference in ED intake between the excellent vs. the no
change/poor (747 ± 46 vs. 267 ± 46 g, p < 0.001) and between
the good vs. the no change/poor (607 ± 172 vs. 267 ± 46 g,
p < 0.006) in ED intake in the first course, and between the
excellent vs. the good (600 ± 128 vs. 450 ± 128 g, p = 0.034)
in ED intake in the second course, and between the excellent
vs. the good (1290 ± 244 vs. 923 ± 239 g, p = 0.009) in total
ED intake in the first plus second courses (Table 3).
The severity of oral mucositis showed a tendency to in-
crease with the severity of neutropenia, in the prior chemo-
therapy course (p = 0.083) (data not shown). The neutropenia
was improved particularly by the second treatment with the
ED (p < 0.327, prior treatment vs. first treatment; p = 0.038,
prior treatment vs. second treatment) (Fig. 2).
Logistic regression analysis for the factors relating
to the efficacy by the ED on oral mucositis
Among the 44 courses of ED in the 22 patients, the efficacy
was excellent in 14 courses, good in another 24 courses, and
no change/poor in the other 6 course (Table 2). The logistic
regression analysis revealed that prior administration of ED,
the dose reduction in 5-FU or oral fluoropyrimidine, and the
ED intake were each an independent significant factor statis-
tically correlated to the preventive efficacy by the ED (the
excellent) on the oral mucositis (Table 4).
Discussion
In the present pilot study, the findings indicated that the
amino-acid-rich ED Elental® might reduce the incidence and
severity of oral mucositis dose-dependently in metastatic co-
lorectal cancer patients receiving fluorouracil-based chemo-
therapy. However, 5 of the 22 patients (23 %) received dose
reductions of 5-FU or oral fluoropyrimidine in chemotherapy
in the cycles after Elental® diet. This dose reduction itself
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Fig. 2 Preventive effects by the ED on neutropenia. The neutropenia was
significantly improved (p < 0.327, prior treatment vs. first treatment;
p = 0.038, prior treatment vs. second treatment) by treatment with the ED
Table 3 The efficacy of ED on oral mucositis and the ED intake
Efficacy First treatment Second treatment
Excellent 3 cases/747 ± 46 g 8 cases/600 ± 128 g (1290 g)
Good 12 cases/607 ± 172 g 8 cases/450 ± 128 g (923 g)
No change/poor 3 cases/267 ± 46 g 2 cases/600 ± 509 g (1160 g)
(): total intake of ED (first plus second treatment courses). First treatment:
p = 0.197 (excellent vs. good), p < 0.001 (excellent vs. no change/poor),
p = 0.006 (good vs. no change/poor). Second treatment: p = 0.034 (ex-
cellent vs. good), p = 0.406 (good vs. no change/poor). First plus second
treatments: p = 0.009 (excellent vs. good), p = 0.699 (excellent vs. no
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Fig. 1 Preventive effects by the ED on oral mucositis. The oral mucositis
was significantly reduced (p = 0.004, prior treatment vs. first treatment;
p < 0.001, prior treatment vs. second treatment) by the ED
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reason for the significant difference. Our additional analysis
only in those patients who received the same dose of chemo-
therapy before and after Elental® therapy confirmed the simi-
lar efficacy of Elental®. The maximum grade of oral mucositis
decreased in 13 of 17 patients during the first course and in 15
of 17 patients in the second course, compared to those in the
prior chemotherapy course. The grade of oral mucositis was
significantly reduced by the ED treatment (p < 0.0001, prior
treatment vs. first treatment; p < 0.0001, prior treatment vs.
second treatment) (data not shown). The logistic regression
multivariate analysis revealed that the pretreatment with the
ED and the ED intake were important for prevention of oral
mucositis by the ED as well as the dose reduction in fluoro-
uracil. The results suggest a possible significance of the nour-
ishment intervention for prevention of chemotherapy-induced
oral mucositis.
It is known that cancer produces a state of glutamine deficien-
cy [12], and many nutritional supplements are designed with
cancer patients in mind to contain free L-glutamine, which is
the preferred substrate for enterocytes within the GI tract. L-Glu-
tamine encourages protein synthesis, enterocyte proliferation,
and antiinflammatory effects—each of which plays a role in
preventing mucositis [8, 13, 14]. In advanced colorectal cancer
patients receiving 5-FU/LV chemotherapy, Choi et al. [15] re-
ported the preventive efficacy of high-dose peroral glutamine
(30 g/day) on oral mucositis. However in general, the systemic
administration of L-glutamine alone is not recommended by the
Clinical Practice Guidelines for Prevention and Treatment of
Mucositis of the Mucositis Study Section of the Multinational
Association of Supportive Care in Cancer and the International
Society for Oral Oncology (MASCC/ISOO) in 2007 [16]. In the
present pilot study, we used a small dose of L-glutamine ranging
from 5.8 to 27 g during the 14 or 21 days of chemotherapy.
Therefore, the efficacy of the ED for preventing oral mucositis
is thought to depend on general nutritional intervention involv-
ing a well-balanced amino acid mixture including L-glutamine,
rather than on L-glutamine alone.
It is reported that the severity of the neutropenia has been
associated with the incidence and severity of chemotherapy-
induced oralmucositis [17]. Of interest, nourishment intervention
using ED in the present study apparently controlled the neutro-
phil depletion, suggesting the potential of nourishment interven-
tion as an adverse-event measure in cancer chemotherapy. It has
been shown that anorexia promotes the generation of other ad-
verse experiences [18], suggesting the importance of the nutri-
tional intervention in cancer chemotherapy. Individual amino
acids such as glutamine and arginine which are main constituents
of the ED may prevent neutropenia via activation of cellular
immunity [19]. However, treatment with glutamine or arginine
alone seems to be insufficient for preventing neutropenia [14]. It
is expected that the relationship between the nutrient state and the
preventive effects of nutritional intervention on neutropenia and
the oral mucositis may be clarified by future studies.
Recently, some studies are reported on keratinocyte growth
factor (palifermin) [20, 21] and a sustained-release drug of
glutamine (Saforis) [22] reducing the incidence of
chemotherapy-induced mucositis. The Food and Drug Ad-
ministration (FDA) of the United States Department of Health
andHuman Services approved palifermin as prevention and as
a treatment for oral mucositis in blood cancer patients who
develop marrow toxicity and need hemopoietic stem cell
transplantation. However, another consideration is the high
cost of these new drugs [23] for introduction into clinical
practice. Therefore, nourishment intervention using ED for
oral mucositis should be considered alongside other standard
oral care for sustaining the patient’s QOL.
We conclude that the amino-acid-rich elemental diet
Elental® may be useful as a countermeasure for 5-FU-based
chemotherapy-induced oral mucositis in patients with colorec-
tal cancer in association with controlling neutropenia. The
findings from this prospective pilot study warrant the initia-
tion of a new clinical study with nutritional intervention in
colorectal cancer patients developing oral mucositis. Howev-
er, this small study makes any conclusions limited. We have
conducted a multicenter clinical study clarifying the preven-
tive effects on oral mucositis by Elental® and its correlation
with change of amino acid balance in the serum.
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Table 4 Multivariate analysis for
the factors related to the efficacy
of the ED on oral mucositis
Factor p value Hazard ratio 95 % CI
Prior administration of ED 0.023 99.423 1.879–5261
Dose reduction of 5-FU/oral fluoropyrimidine 0.034 1019.912 1.674–621,200
ED intake 0.039 1.015 1.001–1.030
Regimen 2 weeks (vs. 3 weeks) 0.051 5.886 0.986–3.418
Male 0.060 230.525 0.800–66,430
Pretreatment albumin value 0.094 75.445 0.482–11,820
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